Xenetic Biosciences, Inc. (NASDAQ:XBIO) Files An 8-K Other EventsItem 8.01 Other Events
On July 18, 2017, Xenetic Biosciences, Inc. (the “Company”) announced that it had rescheduled its 2017 Annual Meeting of Stockholders ("Annual Meeting") for Wednesday, August 16, 2017. This meeting was convened and dismissed without any business being conducted, due to lack of the requisite quorum of shareholder votes either in person or in proxy. The Annual Meeting has been rescheduled for Thursday, October 5, 2017 at a place and time to be determined by the Company’s Board of Directors, to allow additional time for stockholders to receive new proxy materials and vote on the updated proposals to be set forth in the Company's definitive proxy statement, which will be amended or supplemented to include such updated proposals.
A new record date for the Annual Meeting has yet to be determined but will be included in the updated proxy materials, along with the time and location of the Annual Meeting. The Company strongly advises all of its stockholders to read the proxy statement (including any amendments or supplements thereto, once they become available) and other proxy materials relating to the Annual Meeting because they contain important information. Such proxy materials will be available at no charge on the Securities and Exchange Commission's website at www.sec.gov. In addition, copies of the proxy statement (including any amendments or supplements thereto) and other documents may be obtained free of charge by accessing the Company’s website at www.xeneticbio.com or by contacting the Company’s Corporate Secretary at 781-778-7720 or by mail to Corporate Secretary, Xenetic Biosciences, Inc., 99 Hayden Ave., Ste. 230, Lexington, MA 02421.
About Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
